These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12821324)

  • 21. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C.
    Hadziyannis SJ; Papatheodoridis GV
    Expert Opin Pharmacother; 2003 Apr; 4(4):541-51. PubMed ID: 12667117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferons for the treatment of chronic hepatitis C infection.
    Luxon BA; Grace M; Brassard D; Bordens R
    Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy.
    Zeuzem S; Heathcote JE; Martin N; Nieforth K; Modi M
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2201-13. PubMed ID: 11772316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylation of IFN-alpha and antiviral activity.
    Boulestin A; Kamar N; Sandres-Sauné K; Alric L; Vinel JP; Rostaing L; Izopet J
    J Interferon Cytokine Res; 2006 Dec; 26(12):849-53. PubMed ID: 17238827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
    Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
    J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity.
    Lee BK; Kwon JS; Kim HJ; Yamamoto S; Lee EK
    Bioconjug Chem; 2007; 18(6):1728-34. PubMed ID: 17941681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y; Zhai Y; Lei J; Ma G; Su Z
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
    Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
    Shahzadi SK; Qadir MA; Mahmood N; Ahmed M
    Protein Pept Lett; 2020; 27(3):219-224. PubMed ID: 31612813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
    Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
    Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29).
    Youn YS; Na DH; Yoo SD; Song SC; Lee KC
    J Chromatogr A; 2004 Dec; 1061(1):45-9. PubMed ID: 15633743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Site-specific monoPEGylated interferon alpha2a mediated by microbial transglutaminase].
    Hui X; Cao W; Zhang D; Ge W; Li S; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):750-762. PubMed ID: 32347069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
    Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins.
    Lee KC; Moon SC; Park MO; Lee JT; Na DH; Yoo SD; Lee HS; DeLuca PP
    Pharm Res; 1999 Jun; 16(6):813-8. PubMed ID: 10397599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
    Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
    J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
    Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.